DHDaniel F. Hayes

Daniel F. Hayes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel F. Hayes has a total of 949 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Circulating tumor cells in lobular versus ductal metastatic breast cancer

    by Emily M. Dolce, Elizabeth P. Darga, Nicholas C. Henderson, Dafydd G. Thomas, David A. Hanauer, Arul M. Chinnaiyan, Erin F. Cobain, N. Lynn Henry, Costanza Paoletti, Andi K. Cani, et al.

    Purpose: Infiltrating lobular carcinoma (ILC) accounts for ~ 10% of all invasive breast cancer histologies. ILC is associated with worse prognosis than infiltrating ductal cancer. Circulating tumor cells (CTCs) are commonly elevated in metastatic breast cancer (mBC) and elevated levels of CTCs are associated with worse prognosis in breast cancers. We investigated CTC incidence in ILC in two patient cohorts. Methods: Data from electronic medical records at the University of Michigan were identified using the EMERSE search engine to assess CTC levels in patients with mBC, using CellSearch ® . Findings were validated in a separate cohort of mBC patients who participated in a research protocol where CTC were analyzed. Results: Within the EMERSE cohort of 218, 38 (17%), 29 (13%) and 151 (69%) patients, had lobular, mixed, and ductal mBC subtype, respectively. Overall, 101/218 (46%) patients had elevated CTC (≥ 5/7.5 ml whole blood). In this cohort, patients with ILC were more likely to have elevated CTCs (28/38; 74%) compared to those with mixed (14/29; 48%) or ductal (59/151; 39%) mBC ( p = 0.001). In multivariate regression, patients with ILC were seven times more likely than ductal mBC to have elevated CTCs. These data were validated in 146 separate mBC patients in the research cohort. Elevated CTCs were detected in 79%, 31%, and 36% of patients with lobular, mixed and ductal mBC, respectively. Conclusion: CTC are more commonly elevated and tend to be higher in magnitude in patients with lobular compared to ductal mBC. CTC levels in mixed ductal-lobular morphology numerically more resemble ductal mBC.

  • Unlocking 30-Year-Old Archival Formalin-Fixed Paraffin-Embedded Breast Cancer Specimens (SWOG S8897): An Analytical Feasibility Study

    by Donald J. Johann, James Hicks, Kathy S. Albain, William E. Barlow, Andrew K. Godwin, Daniel F. Hayes, Laura F. Hutchins, J. Keith Killian, Erich A. Peterson, Sergio Pina-Oviedo, et al.

    PURPOSE: Thin-cut formalin-fixed paraffin-embedded (FFPE) tumor sections on glass slides represent a large, underused biorepository for precision oncology, but their long-term room temperature storage raises concerns about nucleic acid integrity and analytical validity. We evaluated whether 20- to 30-year-old archival breast cancer FFPE slides could support contemporary DNA and RNA molecular profiling, including tumor subtyping using orthogonal DNA, and RNA-based approaches. METHODS: Two archival cohorts were studied: (1) SWOG S8897 low-risk breast tumors stored as 6-µm unstained FFPE sections on slides for approximately 20-30 years (20 tumors; 19 matched cancer-free lymph nodes [LN]) and (2) similarly aged unrelated FFPE tumor blocks (n = 13) used for assay development. DNA and RNA were extracted with quality assurance/quality control. DNA profiling included low/ultra-low-pass whole genome sequencing for copy number analysis (CNA) and IntClust subtyping plus high-depth targeted sequencing using a 93-gene Unique Molecular Identifier (UMI)–based panel. RNA profiling included RNA-seq on block-derived specimens and a custom droplet digital polymerase chain reaction (ddPCR)–based reverse transcription-quantitative PCR (RT-qPCR) assay to enable subtype calling from highly fragmented RNA. RESULTS: DNA and RNA were recovered from >90% of specimens, despite extensive fragmentation (RNA in a range of 30-100 nt). RNA Access/Exome and NanoString approaches were unsuccessful in the most degraded slide-derived RNAs, prompting development of the ddPCR-based RT-qPCR assay, which successfully quantified targets and enabled intrinsic-like subtype calling across archival tumors. DNA profiling achieved high success for CNA/subtyping and UMI-based mutation detection, and the dual RNA/DNA framework showed strong subtype concordance (ddPCR v IntClust approximately 87% among evaluable cases). CONCLUSION: Decades-old FFPE slide sections, stored at room temperature with no special conditions, can yield usable DNA along with highly degraded RNA for integrated multiomic molecular profiling and breast cancer subtyping. This capability expands access to legacy trial materials with long-term follow-up and supports efficient retrospective and virtual clinical trials.

  • Recurrence Score gene group components and outcomes in the RxPONDER trial (SWOG S1007)

    by Yara Abdou, Jess Hoag, William E Barlow, Kathy S Albain, Julie R Gralow, Funda Meric-Bernstam, Daniel F Hayes, Nancy U Lin, Edith A Perez, Lori J Goldstein, et al.

    Background: The RxPONDER trial has guided adjuvant chemotherapy use in node-positive HR+/HER2– breast cancer; however, prior analyses showed poorer outcomes among non-Hispanic Black (NHB) women compared with non-Hispanic White (NHW) women despite similar 21-gene Recurrence Score (RS) results. This suggests contributors to disparities may not be captured by the composite RS. We evaluated RS gene group components—proliferation, estrogen receptor (ER), HER2 (GRB7), and invasion—by ethnicity, body mass index, and menopausal status, and we assessed associations with outcomes. Methods: RxPONDER enrolled 5083 women with HR+/HER2– breast cancer, 1-3 positive nodes, and RS ≤25, randomly assigned to endocrine therapy ± chemotherapy. In total, 3102 participants with ethnicity and gene expression data were included. RS components were compared across subgroups, and associations with invasive disease-free survival (IDFS) and distant recurrence-free interval were evaluated by using multivariable Cox models adjusted for clinicopathological factors and treatment. Results: Among 3102 women (70.2% NHW, 15.5% Hispanic, 9.5% Asian, 4.7% NHB), RS distributions were similar across groups and prognostic overall. Tumors from NHB (P = .003) and Hispanic women (P = .02) had higher proliferation scores vs NHW women, and Asian women had higher HER2 (P = .006) and ER scores (P = .028). IDFS differences were not statistically significant for NHB vs NHW women (hazard ratio [HR] = 1.41, 95% CI = 0.98 to 2.03), whereas Asian women had improved IDFS (HR = 0.63, 95% CI = 0.43 to 0.91). Conclusions: Despite similar overall RS distributions, component pathways vary by ethnicity and may contribute to outcome differences. These findings support evaluating gene-specific biology beyond composite scores to better understand disparities and refine risk stratification. Trial Registration: ClinicalTrials.gov: NCT01272037


  • Open Access

    Ecological insights from transferable plant biomass mapping across the arctic using high-resolution structure-from-motion and LiDAR data

    by Daryl Yang, Bailey A Murphy, Wouter Hantson, Kathleen M Orndahl, Emma C Hall, Caroline Ludden, Logan T Berner, Andrew M Cunliffe, Michael Alonzo, Mark J Lara, et al.

    Warmer temperatures, permafrost thaw, and increased wildfire activity are driving rapid ecological change across the Arctic, significantly altering plant productivity and aboveground biomass (AGB). These rapid changes highlight the urgent need to improve monitoring of vegetation dynamics in the Earth’s northern ecosystems, where high spatiotemporal heterogeneity occurs at scales finer than those captured by traditional satellite observations. The growing use of unoccupied aerial systems (UASs) presents an opportunity to overcome this limitation. Yet, the diversity of UAS platforms, sensors, and data collection and processing workflows presents challenges for developing standardized, generalizable approaches. To address this challenge, we compiled 672 AGB plots co-located with 183 UAS-based structure-from-motion (SfM) or light detection and ranging (LiDAR) surveys collected across the Arctic. Here, we: (1) evaluated the generalizability of UAS-derived canopy structure derived from high-resolution SfM and LiDAR for estimating AGB, (2) assessed scaling errors and their sources in two recent satellite-based AGB products derived from Landsat and moderate resolution imaging spectroradiometer, and (3) demonstrated the use of high-resolution AGB maps to quantify biomass variation across tundra plant functional types (PFTs) and to monitor post-fire recovery. Our results show that both SfM and LiDAR accurately captured AGB and its variability across tundra PFTs using a random forest model (overall root mean squared error: 0.332 kg m –2 ), with mapping performance varying slightly by region and data source. Using UAS-derived AGB maps as a benchmark, we identified systematic biases in satellite-derived AGB products, largely attributable to the magnitude of AGB and structural heterogeneity within coarse-resolution pixels. Applying our model to repeat UAS surveys following a tundra fire on Seward Peninsula, we observed rapid AGB recovery in non-shrub patches, with biomass recovering to pre-fire levels within two years. In contrast, shrub patches recovered more slowly, with AGB gains continuing over 2–4 years through both in-patch growth and lateral expansion (via dispersal) into remaining burned areas. Overall, these findings support the generalizability of UAS-based SfM and LiDAR data for estimating tundra AGB and highlight the need for broader collection and synthesis of such data to improve ecological monitoring and model benchmarking in the Arctic.

  • Open Access

    Supplementary Table S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis

    by Wolfgang Janni, Thomas W.P. Friedl, Tracy C. Yab, Francois-Clément Bidard, Massimo Cristofanilli, Daniel F. Hayes, Michail Ignatiadis, Meredith M. Regan, Catherine Alix-Panabieres, William E. Barlow, et al.

    Supplementary Table 3: Comparisons of the probabilities of being CTC positive among tumor subtypes (hormone receptor-positive/HER2-negative, HER2-positive, triple-negative) according to time point of CTC assessment (baseline, first follow-up) and cutoff for CTC positivity (≥1 CTC, ≥5 CTCs). Probabilities of being CTC positive are given in terms of percentages and odds ratios with 95% confidence intervals (CI) obtained using binary logistic regression models with the response variable CTC positive (yes vs no)

  • Open Access

    Supplementary Table S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis

    by Wolfgang Janni, Thomas W.P. Friedl, Tracy C. Yab, Francois-Clément Bidard, Massimo Cristofanilli, Daniel F. Hayes, Michail Ignatiadis, Meredith M. Regan, Catherine Alix-Panabieres, William E. Barlow, et al.

    Supplementary Table 1. Clinical trials, multicenter studies, and institutions/centers that provided data sets from MBC patients for the pooled analysis.

  • Open Access

    Supplementary Methods S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis

    by Wolfgang Janni, Thomas W.P. Friedl, Tracy C. Yab, Francois-Clément Bidard, Massimo Cristofanilli, Daniel F. Hayes, Michail Ignatiadis, Meredith M. Regan, Catherine Alix-Panabieres, William E. Barlow, et al.

  • Open Access

    Supplementary Table S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis

    by Wolfgang Janni, Thomas W.P. Friedl, Tracy C. Yab, Francois-Clément Bidard, Massimo Cristofanilli, Daniel F. Hayes, Michail Ignatiadis, Meredith M. Regan, Catherine Alix-Panabieres, William E. Barlow, et al.

    Supplementary Table 2. Absolute and relative frequencies of CTC change groups and percentage of CTC responders (as categorized according to the ≥1 CTC or ≥5 CTC cutoff for CTC positivity) overall, according to tumor subtypes and according to treatment type.

  • Open Access

    Supplementary Figure S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis

    by Wolfgang Janni, Thomas W.P. Friedl, Tracy C. Yab, Francois-Clément Bidard, Massimo Cristofanilli, Daniel F. Hayes, Michail Ignatiadis, Meredith M. Regan, Catherine Alix-Panabieres, William E. Barlow, et al.

    Supplementary Figure 2: Kaplan-Meier plots of overall survival (OS) according to CTC status at baseline for a cutoff for CTC positivity ≥1 CTC (A, B, C) and a cutoff for CTC positivity ≥5 CTCs (D, E, F). Survival time is given as time since baseline CTC assessment in months. (A, D) hormone receptor-positive/HER2-negative tumors; (B, E) HER2- positive tumors; (C, F) triple-negative tumors. The P-values refer to pairwise comparisons with the log rank test.